Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis

References

• O’Donnell AE. Bronchiectasis. Chest. 2008;134:815–823.
   PubMed Web of Science ®Google Scholar
• Pasteur MC, Bilton D, Hill AT; British Thoracic Society Bronchiectasis non-CF Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010;65(Suppl 1):1–58.
   PubMed Web of Science ®Google Scholar
• King PT. The pathophysiology of bronchiectasis. Int J Chron Obstruct Pulmon Dis. 2009;4:411–419.
   PubMedGoogle Scholar
• Seitz AE, Olivier KN, Steiner CA, et al. Trends and burden of bronchiectasis-associated hospitalizations in the United States, 1993–2006. Chest. 2010;138(4):944–949.
   PubMed Web of Science ®Google Scholar
• Weycker D, Edelsberg J, Oster G, et al. Prevalence and economic burden of bronchiectasis. Clin Pulm Med. 2005;12(4):205–209.
   Google Scholar
• Joish VN, Spilsbury-Cantalupo M, Operschall E. Economic burden of non-cystic fibrosis bronchiectasis in the first year after diagnosis from a US health plan perspective. Appl Health Econ Health Policy. 2013;11(3):299–304.
   PubMedGoogle Scholar
• Lonni S, Chalmers JD, Goeminne PC, et al. Etiology of non-cystic fibrosis bronchiectasis in adults and its correlation to disease severity. Ann Am Thorac Soc. 2015;12(12):1764–1770.
   PubMed Web of Science ®Google Scholar
• McShane PJ, Naureckas ET, Tino G, et al. Non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2013;188:647–656.
   PubMed Web of Science ®Google Scholar
• Cole PJ. Inflammation: a two-edged sword – the model of bronchiectasis. Eur J Respir Dis. 1986;Suppl 147:6–15.
   Google Scholar
• Chalmers JD, Goeminne P, Aliberti S, et al. The Bronchiectasis Severity Index. An international derivation and validation study. Am J Respir Crit Care Med. 2014;189:576–585.
   PubMed Web of Science ®Google Scholar
• Loebinger MR, Wells AU, Hansell DM, et al. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J. 2009;34:843–849.
   PubMed Web of Science ®Google Scholar
• Goeminne PC, Nawrot TS, Ruttens D, et al. Mortality in non-cystic fibrosis bronchiectasis: a prospective cohort analysis. Respir Med. 2014;108:287–296.
   PubMed Web of Science ®Google Scholar
• Martínez-García MA, Soler-Cataluña J-J, Perpiñá-Tordera M, et al. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest. 2007;132(5):1565–1572.
   PubMed Web of Science ®Google Scholar
• McDonnell M, Goeminne P, Alberti S, et al. Comparative analysis of the predictive utility of clinical disease severity scores for non-cystic fibrosis bronchiectasis. Eur Resp J. 2014;44(Suppl 58) [cited 2016 Mar 14]. Available from: http://erj.ersjournals.com/content/44/Suppl_58/P2484
   Google Scholar
• Chalmers JD, Aliberti S, Blasi F. Management of bronchiectasis in adults. Eur Respir J. 2015;45:1446–1462.
   PubMed Web of Science ®Google Scholar
• Hill AT, Routh C, Welham S. National BTS bronchiectasis audit 2012: is the quality standard being adhered to in adult secondary care? Thorax. 2014;69:292–294.
   PubMed Web of Science ®Google Scholar
• Zhou Y-M, Wang C, Yao W-Z, et al. [The prevalence and risk factors of bronchiectasis in residents aged 40 years old and above in seven cities in China]. Zhonghua Nei Ke Za Zhi. 2013;52(5):379–382. Chinese.
   PubMedGoogle Scholar
• Quint JK, Millett ERC, Joshi M, et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004–2013: a population based cohort study. Eur Respir J. 2015;47(1):186–193.
   PubMed Web of Science ®Google Scholar
• Seitz AE, Olivier KN, Adjemian J, et al. Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007. Chest. 2012;142:432–439.
   PubMed Web of Science ®Google Scholar
• Ringshausen FC, De Roux A, Diel R, et al. Bronchiectasis in Germany: a population based estimation of disease prevalence. Eur Respir J. 2015;46(6):1805–1807.
   PubMed Web of Science ®Google Scholar
• O’Donnell AE. Bronchiectasis: which antibiotics to use and when? Curr Opin Pulm Med. 2015;21:272–277.
   PubMed Web of Science ®Google Scholar
• Weers J. Inhaled antimicrobial therapy – barriers to effective treatment. Adv Drug Deliv Rev. 2014;85:24–43.
   PubMed Web of Science ®Google Scholar
• Murray MP, Govan JR, Doherty CJ, et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2011;183(4):491–499.
   PubMed Web of Science ®Google Scholar
• Bilton D, Daviskas E, Anderson SD, et al. Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis. Chest. 2013;144:215–225.
   PubMed Web of Science ®Google Scholar
• Bilton D, Tino G, Barker AF, et al. Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial. Thorax. 2014;69:1073–1079.
   PubMed Web of Science ®Google Scholar
• Haworth CS, Foweraker JE, Wilkinson P, et al. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med. 2014;189:975–982.
   PubMed Web of Science ®Google Scholar
• Barker AF, O’Donnell AE, Flume P, et al. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised, double-blind, placebo-controlled phase 3 trials. Lancet Respir Med. 2014;2:738–749.
   PubMed Web of Science ®Google Scholar
• Serisier DJ, Bilton D, De Soyza A, et al. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax. 2013;68:812–817.
   PubMed Web of Science ®Google Scholar
• National Institutes of Health. 2016. Phase 3 study with dual release ciprofloxacin for inhalation in NCFB (ORBIT-3) [cited 2016 Mar 9]. Available from: https://clinicaltrials.gov/ct2/show/NCT01515007
   Google Scholar
• National Institutes of Health. 2016. Phase 3 study with dual release ciprofloxacin for inhalation in NCFB (ORBIT-4) [cited 2016 Mar 9]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT02104245
   Google Scholar
• National Institutes of Health. 2016. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis (non-CF BE) (RESPIRE 1) [cited 2016 Mar 9]. Available from: https://clinicaltrials.gov/ct2/show/NCT01764841
   Google Scholar
• National Institutes of Health. 2016. Ciprofloxacin dry powder for inhalation (DPI) in non-cystic fibrosis bronchiectasis (non-CF BE) (RESPIRE 2) [cited 2016 Mar 9]. Available from: https://clinicaltrials.gov/ct2/show/NCT02106832
   Google Scholar
• AIR-BX1. Safety and effectiveness of AZLI (an inhaled antibiotic) in adults with non-cystic fibrosis bronchiectasis [cited 2016 Mar 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT01313624?term=NCT01313624&rank=1
   Google Scholar
• AIR-BX2. Safety and effectiveness of AZLI (an inhaled antibiotic) in adults with noncystic fibrosis bronchiectasis [cited 2016 Mar 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT01314716?term=NCT01314716&rank=1
   Google Scholar
• Inhaled Promixin® in the treatment of noncystic fibrosis bronchiectasis [cited 2016 Mar 10]. Available from: http://www.controlled-trials.com/ISRCTN49790596
   Google Scholar
• Ciprofloxacin summary of product characteristics [cited 2016 Mar 9]. Available from: https://www.medicines.org.uk/emc/medicine/20346/SPC/Ciproxin+Tablets+500mg/#PHARMACODYNAMIC_PROPS
   Google Scholar
• Ciprofloxacin European Medicines Agency report, annex 1. List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration, marketing authorisation holders in the member states [cited 2016 Mar 6]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Ciprofloxacin_Bayer_30/WC500008075.pdf
   Google Scholar
• Weers JG, Tarara TE. The PulmoSphere™ platform for pulmonary drug delivery. Ther Deliv. 2014;5:277–295.
   PubMedGoogle Scholar
• Quon BS, Goss CH, Ramsey BW. Inhaled antibiotics for lower airway infections. Ann Am Thorac Soc. 2014;11(3):425–434.
   PubMedGoogle Scholar
• Alhaddad B, Smith FJ, Robertson T, et al. Patients’ practices and experiences of using nebuliser therapy in the management of COPD at home. BMJ Open Resp Res. 2015. doi:10.1136/bmjresp-2014-000076
   PubMedGoogle Scholar
• Geller DE, Weers J, Heuerding S. Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere technology. J Aerosol Med Pulm Drug Deliv. 2011;24:175–182.
   PubMed Web of Science ®Google Scholar
• Lam J, Vaughan S, Parkins MD. Tobramycin inhalation powder (TIP): an efficient treatment strategy for the management of chronic Pseudomonas aeruginosa infection in cystic fibrosis. Clin Med Insights Circ Resp Pulm Med. 2013;7:61–77.
   PubMedGoogle Scholar
• Endermann R, Labischinski H, Ladel C, et al. Treatment of bacterial diseases of the respiratory organs. US20040254194 A1 (2004)
   Google Scholar
• Stass H, Nagelschmitz J, Willmann S, et al. Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a Phase I study. Clin Drug Investig. 2013;33:419–427.
   PubMed Web of Science ®Google Scholar
• Stass H, Badorrek P, Hohlfeld J, et al. Safety and pharmacokinetics of multiple-dose ciprofloxacin dry powder for inhalation in patients with moderate or severe chronic obstructive pulmonary disease. Presented at the European Respiratory Society Annual Congress; 2011 Sep 24–28; Amsterdam, The Netherlands; [Poster 3011].
   Google Scholar
• Tokimatsu I, Hiramatsu K, Morimoto T, et al. Safety, tolerability, and pharmacokinetics of a single dose of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) in Japanese patients with mild to moderate chronic obstructive pulmonary disease: a randomized controlled trial. Presented at the International Conference of the American Thoracic Society; 2011 May 13–18; Denver, CO, USA; [Abstract 3106].
   Google Scholar
• Kadota J, Tokimatsu I, Hiramatsu K, et al. A randomized controlled study to investigate the safety and pharmacokinetics of multiple doses of ciprofloxacin dry powder for inhalation in Japanese patients with moderate to severe COPD. Presented at the International Conference of the American Thoracic Society; 2012 May 18–23; California, CA, USA; [Poster 30923].
   Google Scholar
• Stass H, Nagelschmitz J, Watz H, et al. Safety and pharmacokinetics of two dose strengths of ciprofloxacin dry powder for inhalation (DPI) in patients with moderate to severe COPD. Presented at the European Respiratory Society Annual Congress; 2012 Sep 3; Vienna, Austria; [Abstract 2817].
   Google Scholar
• Stass H, Weimann B, Nagelschmitz J, et al. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study. Clin Ther. 2013;35:1571–1581.
   PubMed Web of Science ®Google Scholar
• Stass H, Delesen H, Nagelschmitz J, et al. Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study. J Aerosol Med Pulm Drug Deliv. 2015;28:106–115.
   PubMed Web of Science ®Google Scholar
• Stass H, Nagelschmitz J, Kappeler D, et al. Lung deposition of ciprofloxacin dry powder for inhalation in healthy subjects and patients suffering from chronic obstructive pulmonary disease or non-cystic fibrosis bronchiectasis. Presented at the International Conference of the American Thoracic Society; 2013 May 19; Philadelphia, PA, USA; [Abstract 1507].
   Google Scholar
• Schwarz C. Colobreathe for the treatment of cystic fibrosis-associated pulmonary infections. Pulm Ther. 2015;1:19–30.
   Google Scholar
• Dorkin HL, Staab D, Operschall E, et al. Ciprofloxacin DPI: a randomised, placebo-controlled, phase IIb efficacy and safety study on cystic fibrosis. BMJ Open Respir Res. 2015. eCollection 2015. doi:10.1136/bmjresp-2015-000100
   PubMedGoogle Scholar
• Elborn JS. Ciprofloxacin dry powder inhaler in cystic fibrosis. BMJ Open Resp Res. 2016;3. doi:10.1136/bmjresp-2015-000125
   PubMedGoogle Scholar
• Wilson R, Welte T, Polverino E, et al. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J. 2013;41:1107–1115.
   PubMed Web of Science ®Google Scholar
• Aksamit T, De Soyza A, Operschall E, et al. A comparison of study designs of inhaled agents in non-cystic fibrosis bronchiectasis (NCFB): key differences in the phase 3 RESPIRE trials of ciprofloxacin dry powder for inhalation (DPI). Chest. 2015. doi:10.1378/chest.2277297
   PubMed Web of Science ®Google Scholar
• De Soyza A, Aksamit T, Operschall E, et al. LATE-BREAKING ABSTRACT: baseline demographic profile of subjects of the phase 3 RESPIRE 1 trial of ciprofloxacin dry powder for inhalation (DPI) in non-cystic fibrosis bronchiectasis (NCFB). Eur Resp J. 2015;46(Suppl 59). doi:10.1183/13993003.congress-2015.PA2617
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Aliberti S, Polverino E, et al. The EMBARC European bronchiectasis registry: protocol for an international observational study. ERJ Open Res. 2015;45(5):1446–1462. doi:10.1183/23120541.00081-201
   Google Scholar
• McDonnell MJ, Jary HR, Perry A, et al. Non cystic fibrosis bronchiectasis: a longitudinal retrospective observational cohort study of Pseudomonas persistence and resistance. Respir Med. 2014;109:716–726.
   PubMed Web of Science ®Google Scholar
• Finch S, McDonnell MJ, Abo-Leyah H, et al. A comprehensive analysis of the impact of Pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis. Ann Am Thorac Soc. 2015;12:1602–1611.
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Smith MP, McHugh BJ, et al. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non–cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2012;186(7):657–665.
   PubMed Web of Science ®Google Scholar
• Winthrop K, Aksamit TR, Olivier KN, et al. The respiratory microbiology of patients with nontuberculous mycobacteria from the United States bronchiectasis research registry. Am J Respir Crit Care Med. 2013;187:A4541.
   Google Scholar
• EMBARC presentation at the European Respiratory Society congress 2015. The management of bronchiectasis in Europe [cited 2016 Mar 29]. Available from: https://www.bronchiectasis.eu/ers2015
   Google Scholar
• Henkle E, Daley CL, Griffith DE, et al. Patterns of pharmacotherapy for non-cystic fibrosis bronchiectasis (abstract). Am J Respir Crit Care Med. 2015;191:A2445.
   Google Scholar
• TOBI Podhaler package insert 2015 [cited 2015 Mar 9]. Available from: http://www.pharma.us.novartis.com/product/pi/pdf/tobipodhaler.pdf
   Google Scholar
• Hurst JR, Elborn JS, De Soyza A. COPD–bronchiectasis overlap syndrome. Eur Respir J. 2015;45(2):310–313.
   PubMed Web of Science ®Google Scholar